Skip to content

MorphoSys + Constellation PharmaceuticalsAdvancing Cancer Care in Hematology-Oncology and Solid Tumors

MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma

View Infographic

MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash. This transaction bolsters MorphoSys’s position in hematology-oncology and expands our reach into solid tumors, further advancing our mission in the fight against cancer.

MorphoSys also announced that it has entered into a strategic funding partnership with Royalty Pharma plc (Nasdaq: RPRX), enabling us to fund our growth for years to come.

Press Releases

June 16, 2021

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals

June 2, 2021

MorphoSys to Acquire Constellation Pharmaceuticals

Events and Presentations

8:00 AM EST / 2:00 PM CEST, 06/02/2021 - MorphoSys to Acquire Constellation Pharmaceuticals Investor Conference Call


MorphoSys SEC Filings

Constellation Pharmaceuticals SEC Filings